secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001193125-25-081592
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma prices $20M public offering; $13.1M cash; runway into Q2 2026
---------------------------------------------------------------------------

- Pricing of 13.53M common shares + warrants at $0.79/unit; $20M gross proceeds.
- Net proceeds estimated at $18M; closing expected April 16, 2025.
- Preliminary cash and cash equivalents of $13.1M as of March 31, 2025 (unaudited).
- Including $12M upfront from Boehringer Ingelheim deal, cash runway extended into Q2 2026.
- Offering includes pre-funded warrants for 11.47M shares at $0.001 exercise price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000119312525081592/0001193125-25-081592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000119312525081592/d923668d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-081592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer